Also, our study population was restricted to patients with type 2 diabetes who had baseline less than HbA1c of 8.5% and BMI ≥ 23 kg/m2 and not use insulin, glucagon-like peptide 1 agonist. The gene discussed is INS; the disease is type 2 diabetes mellitus.